Biological markers and prognostic scoring systems in chronic lymphocytic leukaemia

IX. Chronic lymphocytic leukaemia: new genetic markers as prognostic factors.

In Western countries, chronic lymphocytic leukaemia (CLL) is the most frequent mature B-cell malignancy [1]. The course of CLL ranges from very indolent, with a nearly normal life expectancy, to rapidly progressive leading to early death. Understand the genetic basis of CLL may help in clarifying the molecular determinants of this clinical heterogeneity and improve patients’ prognostication. Re...

Prognostic factors in chronic lymphocytic leukaemia (CLL)

Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia

The clinical course of patients with chronic lymphocytic leukemia (CLL) is highly heterogeneous. Gene expression analyses have revealed that leukemic cells with unmutated immunoglobulin heavy chain genes (IgV H ) differ from CLL cells with mutated IgV H in the expression level of some genes, i.e. encoding kinase ZAP-70 and antigen CD38. Recently, additional markers in CLL, including the express...

Angiogenic factor VEGF and its relationship with biological prognostic markers in chronic lymphocytic leukemia.

B-CLL is a heterogeneous disease, distinguishing between good and poor prognosis represents a challenge to hematologists. The present study aimed to assess the relative merit of VEGF as a prognostic factor in CLL and to correlate it with other prognostic factors as CD38 & sP53 in the different stages of the disease. The median values of CD38%, sP53 and VEGF were significantly higher in both hig...

Chronic lymphocytic leukaemia.

Chronic lymphocytic leukaemia is the commonest of the leukaemias and occurs most often in the elderly. The identification of presenting features that correlate adversely or favourably with survival has allowed the rational development of new treatment strategies.